Passage Bio, Inc. (PASG)
Nasdaq: PASG · Biological Products, (No Diagnostic Substances) · Philadelphia, PA · filing with the SEC since 2019
Income statement, as filed
In thousands of US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Period ending | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
| Report filed | Mar 3, 2026 | Mar 4, 2025 | Mar 4, 2024 | Mar 6, 2023 | Mar 3, 2022 | Mar 3, 2021 | · |
| Research and development | 23,276 | 40,179 | 61,419 | 86,053 | 117,673 | 81,788 | 29,738 |
| General and administrative | 19,875 | 24,988 | 41,580 | 49,341 | 60,056 | 30,114 | 6,951 |
| Operating income | -49,296 | -70,400 | -108,389 | -138,394 | -185,729 | -112,902 | -37,189 |
| Interest and investment income | · | · | · | 2,269 | 343 | 670 | 696 |
| Interest income (expense), net | · | · | · | · | · | 0 | · |
| Other income (expense), net | 3,774 | 5,633 | 6,327 | 2,269 | · | · | · |
| Income tax expense | 0 | 0 | · | · | · | · | · |
| Net income | -45,522 | -64,767 | -102,062 | -136,125 | -185,386 | -112,232 | -45,634 |
| Earnings per share, basic | -14.35 | -21.04r | -36.4921b | -49.0485b | -68.2755b | -57.0924b | · |
| Earnings per share, diluted | -14.35 | -21.04r | -36.4921b | -49.0485b | -68.2755b | -57.0924b | · |
| Earnings per share, basic and diluted | · | · | · | · | · | -57.0924b | -211.3008b |
| Weighted average shares, basic | 3,172,870 | 3,078,665r | 2,790,276b | 2,774,247b | 2,718,942b | 1,968,256b | · |
| Weighted average shares, diluted | 3,172,870 | 3,078,665r | 2,790,276b | 2,774,247b | 2,718,942b | 1,968,256b | · |
| Weighted average shares, basic and diluted | · | · | · | · | · | 1,968,256b | 215,912b |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.Share counts and per-share figures are on the newest report's basis, after the change of share basis.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Research and development spent on inventing what it sells next
us-gaap:ResearchAndDevelopmentExpense
us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostGeneral and administrative the cost of running the company itself
us-gaap:GeneralAndAdministrativeExpenseOperating income profit from running the business, before interest and tax
us-gaap:OperatingIncomeLossInterest and investment income what its cash and investments earned
us-gaap:InvestmentIncomeNet
us-gaap:InvestmentIncomeInterestInterest income (expense), net interest earned less interest paid, outside the business
us-gaap:InterestIncomeExpenseNonoperatingNetOther income (expense), net gains and costs outside the business
us-gaap:OtherNonoperatingIncomeExpenseIncome tax expense tax charged on the period's profit
us-gaap:IncomeTaxExpenseBenefitNet income the profit or loss that belongs to the company's shareholders
us-gaap:NetIncomeLossEarnings per share, basic net income per share outstanding
us-gaap:EarningsPerShareBasicEarnings per share, diluted net income per share, counting every share that could be issued
us-gaap:EarningsPerShareDilutedEarnings per share, basic and diluted net income per share, where both counts are the same
us-gaap:EarningsPerShareBasicAndDilutedWeighted average shares, basic the average count of shares outstanding
us-gaap:WeightedAverageNumberOfSharesOutstandingBasicWeighted average shares, diluted the average count with every share that could be issued
us-gaap:WeightedAverageNumberOfDilutedSharesOutstandingWeighted average shares, basic and diluted the average count, where both counts are the same
us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted